



Cornerstone Pharmaceuticals, Inc.
1 Duncan Drive
Cranbury, NJ 08512

Media Contact: Aaron Estrada
The Ruth Group
(646) 536 -7028
astrada@theruthgroup.com

CORNERSTONE PHARMACEUTICALS' CPI-613 DATA TO BE PRESENTED AT THE 2014 ANNUAL AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING

CRANBURY, NEW JERSEY (April 18, 2014) – Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that data from a Phase I clinical trial of its proprietary first-in-class anticancer compound CPI-613 in patients with relapsed or refractory acute myeloid leukemia (AML) has been selected to be part of the Poster Highlights Session of the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place, Chicago, IL, May 30-June 3, 2014. The data will be presented by Dr. Timothy S. Pardee, the Principal Investigator for the trial sponsored by the Comprehensive Cancer Center of Wake Forest Baptist Medical Center. The time and date of the session are expected to be available on the ASCO website, <http://am.asco.org>, in mid-May.

The poster is titled: "A phase I study of the mitochondrial metabolism inhibitor CPI-613 in combination with high dose Ara-C (HDAC) and mitoxantrone for relapsed or refractory acute myeloid leukemia (AML)."

CPI-613 is the lead drug candidate from Cornerstone's proprietary Altered Energy Metabolism Directed (AEMD) platform. Cornerstone's AEMD drug platform disrupts biochemical alterations in the conversion of glucose to energy that occur in many types of cancer cells. These essential "bioenergetic" differences are linked to pathways that support, among other things, cancer cell growth and development. CPI- 613 is currently being evaluated in Phase I/II trials.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the differences between normal cells and cancer cells. The company's primary objective is to produce highly selective and effective agents with minimal toxic effects on normal cells and tissues. The company's unique approach to targeting cancer metabolism has led to two distinct technology platforms: altered energy metabolism directed, or AEMD, compounds and an Emulsiphon lipid nanoemulsion based drug delivery system. www.cornerstonepharma.com.

###

This release contains forward-looking statements. These statements relate to future events or the company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate",



"predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.